Lymphoplasmacytic lymphoma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Line 6: Line 6:
The [[prevalence]] of [[lymphoplasmacytic lymphoma]] is estimated to be 1000-1500 cases in United States annually. [[Lymphoplasmacytic lymphoma]] represents 1-2% of all [[hematological]] [[Cancer|cancers]].
The [[prevalence]] of [[lymphoplasmacytic lymphoma]] is estimated to be 1000-1500 cases in United States annually. [[Lymphoplasmacytic lymphoma]] represents 1-2% of all [[hematological]] [[Cancer|cancers]].


==[[Epidemiology]] and [[Demographics]]==
==Epidemiology and Demographics==
*[[Lymphoplasmacytic lymphoma]] is one of the rare subtypes of [[NHL]] accounting just 1-2% of it.
*[[Lymphoplasmacytic lymphoma]] is one of the rare subtypes of [[NHL]] accounting just 1-2% of it.
===[[Prevalence]]:===
===Prevalence:===
* The [[prevalence]] of [[lymphoplasmacytic lymphoma]] is estimated to be 1000-1,500 cases in United States annually.<ref name="pmid22139816">{{cite journal| author=Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R et al.| title=Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. | journal=Cancer | year= 2012 | volume= 118 | issue= 15 | pages= 3793-800 | pmid=22139816 | doi=10.1002/cncr.26627 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22139816  }} </ref><ref name="pmid9506352">{{cite journal| author=Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF| title=Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. | journal=Cancer | year= 1998 | volume= 82 | issue= 6 | pages= 1078-81 | pmid=9506352 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9506352  }} </ref>
* The [[prevalence]] of [[lymphoplasmacytic lymphoma]] is estimated to be 1000-1,500 cases in United States annually.<ref name="pmid22139816">{{cite journal| author=Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R et al.| title=Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. | journal=Cancer | year= 2012 | volume= 118 | issue= 15 | pages= 3793-800 | pmid=22139816 | doi=10.1002/cncr.26627 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22139816  }} </ref><ref name="pmid9506352">{{cite journal| author=Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF| title=Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. | journal=Cancer | year= 1998 | volume= 82 | issue= 6 | pages= 1078-81 | pmid=9506352 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9506352  }} </ref>


===[[Incidence]]:===
===Incidence:===
*LPL accounts for approximately 1% to 2% of [[hematologic]] cancers in United States and Western Europe.<ref name="pmid8219203">{{cite journal| author=Herrinton LJ, Weiss NS| title=Incidence of Waldenström's macroglobulinemia. | journal=Blood | year= 1993 | volume= 82 | issue= 10 | pages= 3148-50 | pmid=8219203 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8219203  }} </ref><ref name="pmid9506352">{{cite journal| author=Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF| title=Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. | journal=Cancer | year= 1998 | volume= 82 | issue= 6 | pages= 1078-81 | pmid=9506352 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9506352  }} </ref>
*LPL accounts for approximately 1% to 2% of [[hematologic]] cancers in United States and Western Europe.<ref name="pmid8219203">{{cite journal| author=Herrinton LJ, Weiss NS| title=Incidence of Waldenström's macroglobulinemia. | journal=Blood | year= 1993 | volume= 82 | issue= 10 | pages= 3148-50 | pmid=8219203 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8219203  }} </ref><ref name="pmid9506352">{{cite journal| author=Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF| title=Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. | journal=Cancer | year= 1998 | volume= 82 | issue= 6 | pages= 1078-81 | pmid=9506352 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9506352  }} </ref>
*World-wide, the overall [[age]]-adjusted [[incidence]] of [[lymphoplasmacytic lymphoma]] is 0.38 cases per 100,000 persons annually, increasing with age to 2.85 in patients above 80 years (or 5 cases per 1 million persons per year).<ref name="pmid23901022">{{cite journal| author=Monge J, Braggio E, Ansell SM| title=Genetic factors and pathogenesis of Waldenström's macroglobulinemia. | journal=Curr Oncol Rep | year= 2013 | volume= 15 | issue= 5 | pages= 450-6 | pmid=23901022 | doi=10.1007/s11912-013-0331-7 | pmc=PMC3807757 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23901022  }} </ref>
*World-wide, the overall [[age]]-adjusted [[incidence]] of [[lymphoplasmacytic lymphoma]] is 0.38 cases per 100,000 persons annually, increasing with [[age]] to 2.85 in [[patients]] above 80 years (or 5 cases per 1 million persons per year).<ref name="pmid23901022">{{cite journal| author=Monge J, Braggio E, Ansell SM| title=Genetic factors and pathogenesis of Waldenström's macroglobulinemia. | journal=Curr Oncol Rep | year= 2013 | volume= 15 | issue= 5 | pages= 450-6 | pmid=23901022 | doi=10.1007/s11912-013-0331-7 | pmc=PMC3807757 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23901022  }} </ref>
*Incidence of LPL. is approximately 8.3 cases per million persons per year.<ref name="pmid16150940">{{cite journal| author=Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS| title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. | journal=Blood | year= 2006 | volume= 107 | issue= 1 | pages= 265-76 | pmid=16150940 | doi=10.1182/blood-2005-06-2508 | pmc=1895348 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16150940  }} </ref>
*[[Incidence]] of LPL. is approximately 8.3 cases per million persons per year.<ref name="pmid16150940">{{cite journal| author=Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS| title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. | journal=Blood | year= 2006 | volume= 107 | issue= 1 | pages= 265-76 | pmid=16150940 | doi=10.1182/blood-2005-06-2508 | pmc=1895348 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16150940  }} </ref>
*LPL [[incidence]] is approximately 10-fold lower in Asia.<ref name="pmid23784625">{{cite journal| author=Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y et al.| title=Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003. | journal=Int J Cancer | year= 2014 | volume= 134 | issue= 1 | pages= 174-80 | pmid=23784625 | doi=10.1002/ijc.28343 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23784625  }} </ref>
*LPL [[incidence]] is approximately 10-fold lower in Asia.<ref name="pmid23784625">{{cite journal| author=Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y et al.| title=Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003. | journal=Int J Cancer | year= 2014 | volume= 134 | issue= 1 | pages= 174-80 | pmid=23784625 | doi=10.1002/ijc.28343 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23784625  }} </ref>
*Majority of LPL patients are Caucasians, with other ethnic groups accounting for only 5 percent of cases.<ref name="pmid9506352">{{cite journal| author=Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF| title=Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. | journal=Cancer | year= 1998 | volume= 82 | issue= 6 | pages= 1078-81 | pmid=9506352 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9506352  }} </ref>
*Majority of LPL patients are Caucasians, with other ethnic groups accounting for only 5 percent of cases.<ref name="pmid9506352">{{cite journal| author=Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF| title=Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. | journal=Cancer | year= 1998 | volume= 82 | issue= 6 | pages= 1078-81 | pmid=9506352 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9506352  }} </ref>
Line 21: Line 21:
*Combined [[age]] and sex-adjusted [[incidence]] is 0.57 per 100,000 person-years.<ref name="KyleLarson2018">{{cite journal|last1=Kyle|first1=Robert A.|last2=Larson|first2=Dirk R.|last3=McPhail|first3=Ellen D.|last4=Therneau|first4=Terry M.|last5=Dispenzieri|first5=Angela|last6=Kumar|first6=Shaji|last7=Kapoor|first7=Prashant|last8=Cerhan|first8=James R.|last9=Rajkumar|first9=S. Vincent|title=Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review|journal=Mayo Clinic Proceedings|volume=93|issue=6|year=2018|pages=739–746|issn=00256196|doi=10.1016/j.mayocp.2018.02.011}}</ref>
*Combined [[age]] and sex-adjusted [[incidence]] is 0.57 per 100,000 person-years.<ref name="KyleLarson2018">{{cite journal|last1=Kyle|first1=Robert A.|last2=Larson|first2=Dirk R.|last3=McPhail|first3=Ellen D.|last4=Therneau|first4=Terry M.|last5=Dispenzieri|first5=Angela|last6=Kumar|first6=Shaji|last7=Kapoor|first7=Prashant|last8=Cerhan|first8=James R.|last9=Rajkumar|first9=S. Vincent|title=Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review|journal=Mayo Clinic Proceedings|volume=93|issue=6|year=2018|pages=739–746|issn=00256196|doi=10.1016/j.mayocp.2018.02.011}}</ref>


===[[Age]]:===
===Age:===
* The [[incidence]] of [[lymphoplasmacytic lymphoma]] increases after 50 years of [[age]].<ref name="RF">Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015</ref>
* The [[incidence]] of [[lymphoplasmacytic lymphoma]] increases after 50 years of [[age]].<ref name="RF">Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015</ref>


Line 29: Line 29:
* [[Men]] are twice more likely than women to develop LPL(5.4 vs. 2.7 per million, respectively). <ref name="pmid22139816">{{cite journal| author=Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R et al.| title=Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. | journal=Cancer | year= 2012 | volume= 118 | issue= 15 | pages= 3793-800 | pmid=22139816 | doi=10.1002/cncr.26627 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22139816  }} </ref><ref name="pmid28366781">{{cite journal| author=Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L et al.| title=Waldenström Macroglobulinemia: Review of Pathogenesis and Management. | journal=Clin Lymphoma Myeloma Leuk | year= 2017 | volume= 17 | issue= 5 | pages= 252-262 | pmid=28366781 | doi=10.1016/j.clml.2017.02.028 | pmc=5413391 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28366781  }} </ref><ref name="pmid17488966">{{cite journal| author=Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H et al.| title=Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. | journal=JAMA | year= 2007 | volume= 297 | issue= 18 | pages= 2010-7 | pmid=17488966 | doi=10.1001/jama.297.18.2010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17488966  }} </ref><ref name="pmid8219203">{{cite journal| author=Herrinton LJ, Weiss NS| title=Incidence of Waldenström's macroglobulinemia. | journal=Blood | year= 1993 | volume= 82 | issue= 10 | pages= 3148-50 | pmid=8219203 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8219203  }} </ref>
* [[Men]] are twice more likely than women to develop LPL(5.4 vs. 2.7 per million, respectively). <ref name="pmid22139816">{{cite journal| author=Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R et al.| title=Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. | journal=Cancer | year= 2012 | volume= 118 | issue= 15 | pages= 3793-800 | pmid=22139816 | doi=10.1002/cncr.26627 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22139816  }} </ref><ref name="pmid28366781">{{cite journal| author=Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L et al.| title=Waldenström Macroglobulinemia: Review of Pathogenesis and Management. | journal=Clin Lymphoma Myeloma Leuk | year= 2017 | volume= 17 | issue= 5 | pages= 252-262 | pmid=28366781 | doi=10.1016/j.clml.2017.02.028 | pmc=5413391 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28366781  }} </ref><ref name="pmid17488966">{{cite journal| author=Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H et al.| title=Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. | journal=JAMA | year= 2007 | volume= 297 | issue= 18 | pages= 2010-7 | pmid=17488966 | doi=10.1001/jama.297.18.2010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17488966  }} </ref><ref name="pmid8219203">{{cite journal| author=Herrinton LJ, Weiss NS| title=Incidence of Waldenström's macroglobulinemia. | journal=Blood | year= 1993 | volume= 82 | issue= 10 | pages= 3148-50 | pmid=8219203 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8219203  }} </ref>


===[[Race]]:===
===Race:===
*Higher incidence in whites (4.1 per million per year) comparative to blacks (1.8 per million per year) and in past 20 years, [[incidence]] in whites has elevated.<ref name="pmid22139816">{{cite journal| author=Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R et al.| title=Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. | journal=Cancer | year= 2012 | volume= 118 | issue= 15 | pages= 3793-800 | pmid=22139816 | doi=10.1002/cncr.26627 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22139816  }} </ref><ref name="pmid28366781">{{cite journal| author=Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L et al.| title=Waldenström Macroglobulinemia: Review of Pathogenesis and Management. | journal=Clin Lymphoma Myeloma Leuk | year= 2017 | volume= 17 | issue= 5 | pages= 252-262 | pmid=28366781 | doi=10.1016/j.clml.2017.02.028 | pmc=5413391 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28366781  }} </ref><ref name="pmid16150940">{{cite journal| author=Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS| title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. | journal=Blood | year= 2006 | volume= 107 | issue= 1 | pages= 265-76 | pmid=16150940 | doi=10.1182/blood-2005-06-2508 | pmc=1895348 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16150940  }} </ref><ref name="pmid8219203">{{cite journal| author=Herrinton LJ, Weiss NS| title=Incidence of Waldenström's macroglobulinemia. | journal=Blood | year= 1993 | volume= 82 | issue= 10 | pages= 3148-50 | pmid=8219203 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8219203  }} </ref>
*Higher [[incidence]] in whites (4.1 per million per year) comparative to blacks (1.8 per million per year) and in past 20 years, [[incidence]] in whites has elevated.<ref name="pmid22139816">{{cite journal| author=Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R et al.| title=Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. | journal=Cancer | year= 2012 | volume= 118 | issue= 15 | pages= 3793-800 | pmid=22139816 | doi=10.1002/cncr.26627 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22139816  }} </ref><ref name="pmid28366781">{{cite journal| author=Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L et al.| title=Waldenström Macroglobulinemia: Review of Pathogenesis and Management. | journal=Clin Lymphoma Myeloma Leuk | year= 2017 | volume= 17 | issue= 5 | pages= 252-262 | pmid=28366781 | doi=10.1016/j.clml.2017.02.028 | pmc=5413391 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28366781  }} </ref><ref name="pmid16150940">{{cite journal| author=Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS| title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. | journal=Blood | year= 2006 | volume= 107 | issue= 1 | pages= 265-76 | pmid=16150940 | doi=10.1182/blood-2005-06-2508 | pmc=1895348 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16150940  }} </ref><ref name="pmid8219203">{{cite journal| author=Herrinton LJ, Weiss NS| title=Incidence of Waldenström's macroglobulinemia. | journal=Blood | year= 1993 | volume= 82 | issue= 10 | pages= 3148-50 | pmid=8219203 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8219203  }} </ref>


=== [[Epidemiology]] and [[demographics]] of Smoldering [[Waldenstrom macroglobulinemia]]: ===  
=== Epidemiology and demographics of Smoldering Waldenstrom macroglobulinemia: ===  
According to a recent study done in 2017, the following data was found out regarding [[epidemiology]] and [[demographics]] of SWM.<ref name="PophaliBartley2017">{{cite journal|last1=Pophali|first1=Priyanka Avinash|last2=Bartley|first2=Adam C.|last3=Kapoor|first3=Prashant|last4=Gonsalves|first4=Wilson I.|last5=Ashrani|first5=Aneel A.|last6=Marshall|first6=Ariela L.|last7=Siddiqui|first7=Mustaqeem Ahmad|last8=Go|first8=Ronald S.|title=Smoldering Waldenström’s macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB).|journal=Journal of Clinical Oncology|volume=35|issue=15_suppl|year=2017|pages=1573–1573|issn=0732-183X|doi=10.1200/JCO.2017.35.15_suppl.1573}}</ref>
According to a recent study done in 2017, the following data was found out regarding [[epidemiology]] and [[demographics]] of smoldering [[Waldenstrom macroglobulinemia]].<ref name="PophaliBartley2017">{{cite journal|last1=Pophali|first1=Priyanka Avinash|last2=Bartley|first2=Adam C.|last3=Kapoor|first3=Prashant|last4=Gonsalves|first4=Wilson I.|last5=Ashrani|first5=Aneel A.|last6=Marshall|first6=Ariela L.|last7=Siddiqui|first7=Mustaqeem Ahmad|last8=Go|first8=Ronald S.|title=Smoldering Waldenström’s macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB).|journal=Journal of Clinical Oncology|volume=35|issue=15_suppl|year=2017|pages=1573–1573|issn=0732-183X|doi=10.1200/JCO.2017.35.15_suppl.1573}}</ref>


{| class="wikitable"
{| class="wikitable"
|+ ''' [[Epidemiology]] and [[demographics]] of Smoldering [[Waldenstrom macroglobulinemia]] according to Sex, Race and Age'''
|+ ''' Epidemiology and demographics of Smoldering Waldenstrom macroglobulinemia according to Sex, Race and Age'''
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk factors
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk factors
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Proportion of SWM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Proportion of Smoldering Waldenstrom Macroglobulinemia
|-
|-
| style="background:#DCDCDC;" align="center" + |Sex
| style="background:#DCDCDC;" align="center" + |Sex
| style="background:#F5F5F5;" align="center" + |Males:27.72%, Females:28.31%
| style="background:#F5F5F5;" align="center" + |
* [[Males]]: 27.72%
* [[Females]]: 28.31%
|-
|-
| style="background:#DCDCDC;" align="center" + |Race
| style="background:#DCDCDC;" align="center" + |[[Race]]
| style="background:#F5F5F5;" align="center" + |White, non-hispanic:28.97%, White, Hispanic:24.79%, Black:21.01%, Asian:20.41%, Other:26.08%.
| style="background:#F5F5F5;" align="center" + |
* White, non-hispanic: 28.97%  
* White, Hispanic: 24.79%  
* Black: 21.01%
* Asian: 20.41%  
* Other: 26.08%
|-
|-
| style="background:#DCDCDC;" align="center" + |Age in years
| style="background:#DCDCDC;" align="center" + |[[Age]] in years
| style="background:#F5F5F5;" align="center" + |18-49:18.32%, 50-64:25.91%, 65-79:30.8%, ≥80 : 27.26%
| style="background:#F5F5F5;" align="center" + |
* 18-49: 18.32%,  
* 50-64: 25.91%,  
* 65-79: 30.8%,  
* ≥80 : 27.26%
|-
|-
|}
|}

Revision as of 21:16, 20 February 2019

Lymphoplasmacytic lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphoplasmacytic Lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphoplasmacytic lymphoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphoplasmacytic lymphoma epidemiology and demographics

CDC on Lymphoplasmacytic lymphoma epidemiology and demographics

Lymphoplasmacytic lymphoma epidemiology and demographics in the news

Blogs on Lymphoplasmacytic lymphoma epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lymphoplasmacytic lymphoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

The prevalence of lymphoplasmacytic lymphoma is estimated to be 1000-1500 cases in United States annually. Lymphoplasmacytic lymphoma represents 1-2% of all hematological cancers.

Epidemiology and Demographics

Prevalence:

Incidence:

  • LPL accounts for approximately 1% to 2% of hematologic cancers in United States and Western Europe.[3][2]
  • World-wide, the overall age-adjusted incidence of lymphoplasmacytic lymphoma is 0.38 cases per 100,000 persons annually, increasing with age to 2.85 in patients above 80 years (or 5 cases per 1 million persons per year).[4]
  • Incidence of LPL. is approximately 8.3 cases per million persons per year.[5]
  • LPL incidence is approximately 10-fold lower in Asia.[6]
  • Majority of LPL patients are Caucasians, with other ethnic groups accounting for only 5 percent of cases.[2]
  • The age-adjusted incidence rate for males is 0.92 per 100,000 person-years.[7]
  • The age-adjusted incidence rate for females is 0.30 per 100,000 person-years.[7]
  • Combined age and sex-adjusted incidence is 0.57 per 100,000 person-years.[7]

Age:

Gender:

  • Men are twice more likely than women to develop LPL(5.4 vs. 2.7 per million, respectively). [1][9][10][3]

Race:

  • Higher incidence in whites (4.1 per million per year) comparative to blacks (1.8 per million per year) and in past 20 years, incidence in whites has elevated.[1][9][5][3]

Epidemiology and demographics of Smoldering Waldenstrom macroglobulinemia:

According to a recent study done in 2017, the following data was found out regarding epidemiology and demographics of smoldering Waldenstrom macroglobulinemia.[11]

Epidemiology and demographics of Smoldering Waldenstrom macroglobulinemia according to Sex, Race and Age
Risk factors Proportion of Smoldering Waldenstrom Macroglobulinemia
Sex
Race
  • White, non-hispanic: 28.97%
  • White, Hispanic: 24.79%
  • Black: 21.01%
  • Asian: 20.41%
  • Other: 26.08%
Age in years
  • 18-49: 18.32%,
  • 50-64: 25.91%,
  • 65-79: 30.8%,
  • ≥80 : 27.26%

References

  1. ↑ 1.0 1.1 1.2 1.3 Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R; et al. (2012). "Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study". Cancer. 118 (15): 3793–800. doi:10.1002/cncr.26627. PMID 22139816.
  2. ↑ 2.0 2.1 2.2 Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF (1998). "Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994". Cancer. 82 (6): 1078–81. PMID 9506352.
  3. ↑ 3.0 3.1 3.2 3.3 Herrinton LJ, Weiss NS (1993). "Incidence of Waldenström's macroglobulinemia". Blood. 82 (10): 3148–50. PMID 8219203.
  4. ↑ Monge J, Braggio E, Ansell SM (2013). "Genetic factors and pathogenesis of Waldenström's macroglobulinemia". Curr Oncol Rep. 15 (5): 450–6. doi:10.1007/s11912-013-0331-7. PMC 3807757. PMID 23901022.
  5. ↑ 5.0 5.1 Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006). "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001". Blood. 107 (1): 265–76. doi:10.1182/blood-2005-06-2508. PMC 1895348. PMID 16150940.
  6. ↑ Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y; et al. (2014). "Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003". Int J Cancer. 134 (1): 174–80. doi:10.1002/ijc.28343. PMID 23784625.
  7. ↑ 7.0 7.1 7.2 Kyle, Robert A.; Larson, Dirk R.; McPhail, Ellen D.; Therneau, Terry M.; Dispenzieri, Angela; Kumar, Shaji; Kapoor, Prashant; Cerhan, James R.; Rajkumar, S. Vincent (2018). "Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review". Mayo Clinic Proceedings. 93 (6): 739–746. doi:10.1016/j.mayocp.2018.02.011. ISSN 0025-6196.
  8. ↑ Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015
  9. ↑ 9.0 9.1 9.2 Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L; et al. (2017). "Waldenström Macroglobulinemia: Review of Pathogenesis and Management". Clin Lymphoma Myeloma Leuk. 17 (5): 252–262. doi:10.1016/j.clml.2017.02.028. PMC 5413391. PMID 28366781.
  10. ↑ Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H; et al. (2007). "Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus". JAMA. 297 (18): 2010–7. doi:10.1001/jama.297.18.2010. PMID 17488966.
  11. ↑ Pophali, Priyanka Avinash; Bartley, Adam C.; Kapoor, Prashant; Gonsalves, Wilson I.; Ashrani, Aneel A.; Marshall, Ariela L.; Siddiqui, Mustaqeem Ahmad; Go, Ronald S. (2017). "Smoldering Waldenström's macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB)". Journal of Clinical Oncology. 35 (15_suppl): 1573–1573. doi:10.1200/JCO.2017.35.15_suppl.1573. ISSN 0732-183X.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Lymphoplasmacytic_lymphoma_epidemiology_and_demographics&oldid=1552988"